Login to Your Account



Financings Roundup

Syndexa's Series B Adds $15M for Metabolic Disease Platform

By Donna Young


Monday, June 2, 2008
Syndexa Pharmaceuticals Corp.'s bank account got a $15 million boost in a Series B financing round, which will allow the firm to advance its metabolic disease product platform. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription